Novo Nordisk Announced Semaglutide 2.4 Mg Reduces The Risk Of Major Adverse Cardiovascular Events By 20% In Adults With Overweight Or Obesity In The Select Trial; Said Trial Achieved Its Primary Objective
Portfolio Pulse from Charles Gross
Novo Nordisk announced that its drug, semaglutide 2.4 mg, has reduced the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial. The trial achieved its primary objective, demonstrating a statistically significant reduction in MACE for people treated with semaglutide 2.4 mg compared to placebo. The drug also had a safe and well-tolerated profile.
August 08, 2023 | 9:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novo Nordisk's semaglutide 2.4 mg has shown positive results in the SELECT trial, reducing cardiovascular risk in overweight or obese adults. This could potentially boost the company's reputation and sales.
The positive results from the SELECT trial for Novo Nordisk's semaglutide 2.4 mg could potentially increase the demand for the drug, leading to increased sales and revenue for the company. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100